About chronic myeloid leukaemia (CML)

CML is a slow-growing type of blood cancer. It starts in blood-forming cells in your bone marrow called myeloid stem cells.

If you have CML, these cells multiply too much. They divide and mature uncontrollably. This leads to an increase in the different types of white blood cells in your blood and bone marrow. As the leukaemia cells build up, they can fill up your bone marrow stopping it make enough healthy red and white blood cells.

CML is quite rare. Only around 830 people in the UK are diagnosed with it every year. That’s about one person in every 100,000.

CML can affect people of any age, but it is most common in people over 60 to 65.

We do not know exactly what causes CML. However, it is not because of anything you have or have not done. You cannot catch CML or pass it on to anyone else.

Some things can increase your chance of getting CML. These include:

• Age (your chance of getting CML increases with age)
• Sex (CML is slightly more common in males than females)
• Exposure to radiation

The signs and symptoms of CML vary from person-to-person. They also depend on how many leukaemia cells you have in your body and where they are.

Some people with CML have no symptoms and are diagnosed after a blood test for something else. But symptoms could include:

• Feeling tired, breathless or dizzy due to a low red blood cell count (anaemia)
• Infections that last a long time or keep coming back
• Fever
• Fatigue
• Unexplained weight loss
• Night sweats
• Tummy pain, bloating or discomfort due to a swollen spleen (you may particularly notice this feeling under your ribs on the left side)
• A feeling of fullness after eating, again due to a swollen spleen
• Bruising easily or bleeding when you wouldn’t usually (for example, nose bleeds or bleeding gums when you brush your teeth)

Your haematology team will diagnose CML based on:

• Blood tests
• Bone marrow tests
• Tests to look for genetic changes in your blood or bone marrow samples

It can be difficult waiting for test results. If you need support, call our freephone Helpline on 08088 010 444.

Blood tests

A blood test called a full blood count measures the number of red blood cells, platelets and different types of white blood cells you have. If you have CML, this usually shows:

• High numbers of white blood cells
• Low numbers of healthy red blood cells

Your platelet count could be high or low.

A specialist also looks at your blood sample under a microscope to see what kind of white blood cells are there. With CML, there is usually a typical pattern of leukaemia cells and different white blood cells at various stages of development.

Depending on the results of your blood tests, your doctor may suggest more specialised tests.

Bone marrow tests

Bone marrow is the spongy part in the middle of some of the large bones in your body. It is where all your blood cells develop.

A bone marrow test helps your haematology team make an accurate diagnosis. It also helps them work out the phase of your CML and look for other changes that might affect your treatment options.

Genetic tests

Leukaemia cells in people with CML show a particular pattern of genetic changes. We do not know why people with CML get these changes. You do not get them from your parents and you cannot pass them on to any children you may have.

If your haematologist thinks you might have CML, they will send your blood or bone marrow samples for genetic tests to confirm the diagnosis.

• The genetic change in people with CML is called the BCR-ABL1 gene.
• In most people with CML, the BCR-ABL1 gene forms when DNA swaps between chromosome 9 and chromosome 22. This makes a chromosome called the Philadelphia chromosome, which contains the BCR-ABL1 gene. Doctors can see the Philadelphia chromosome under a microscope on specialised tests. Some people with CML do not have the typical Philadelphia chromosome but they still have the BCR-ABL1 gene.
• The BCR-ABL1 gene makes an abnormal version of a protein called tyrosine kinase. It is this protein that encourages the blood-forming cells in your bone marrow to make too many white blood cells.

Other tests

You might have blood tests to check how well your liver and kidneys are working. It is also routine to check you for undiagnosed infections such as hepatitis and HIV.

You might have other tests to find out more about how CML is affecting your body. These are not always needed, but they could include:

• An ultrasound scan to see how big your spleen is
• A lumbar puncture to find out if there are any leukaemia cells in the fluid around your brain and spinal cord
• Other tests recommended by your haematology team

Your haematology team will use your test results to work out what phase your CML is in. This helps them recommend the most suitable treatment. There are two main phases:

• Chronic phase: this means that less than 10 to 20 in every 100 cells in your blood or bone marrow are leukaemia cells. Most people are in the chronic phase when they are diagnosed.
• Blast phase: this means your leukaemia is growing more rapidly and you have a higher level of abnormal cells in your blood or bone marrow. If your CML is in the blast phase, you need more intensive treatment.

In some people, test results or symptoms in the chronic phase suggest they might be progressing to the blast phase. Your haematology team might call this the accelerated phase or the chronic phase with high-risk features.

For people diagnosed in chronic phase CML, outcomes are usually excellent. In general, people diagnosed in the chronic phase of CML can expect to live as long as people who do not have CML.

Outcomes are less favourable for people with blast phase CML so it is important to monitor response regularly.

Outcomes vary from person-to-person and depend on many different factors. These include:

• Your age and overall fitness
• The phase of your CML when you were diagnosed
• Your white blood cell counts when you were diagnosed
• Your leukaemia cell type and the genetic changes it has
• Your response to treatment

Your haematology team are best placed to discuss what they expect for you because they know your individual circumstances.

Sources we used to develop this information

Annunziata M, Bonifacio M, Breccia M, Castagnetti F, Gozzini A, Iurlo A, et al. Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia. Front Oncol 2020;10:883.

Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of clinical oncology. 2009 Dec 12;27(35):6041.

Bonifacio M, Stagno F, Scaffidi L, Krampera M, Di Raimondo F. Management of chronic myeloid leukaemia in advanced phase. Front Oncol 2019;9: Art 1132.

Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer 2018;17(1):58.

Garcia-Gutierrez V, Hernandez-Boluda JC. Tyrosine kinase inhibitors available for chronic myeloid leukaemia: Efficacy and safety. Front Oncol 2019;9:Art 603.

Healey MA, Allendorf DJ, Borate U, Madan A. CNS Involvement in a Patient with Chronic Myeloid Leukemia. Case Rep Hematol 2021;2021:8891376.

Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020;34(4):966-984.

Hochhaus A, Saussele S, Rosti G, Mahon FX, Janssen JJWM, Hjorth-Hansen H, et al; ESMO Guidelines Committee. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(suppl_4):iv41-iv51.

Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, et al. Asciminib in chronic myeloid leukaemia after ABL kinase inhibitor failure. N Engl J Med 2019; 381:2315-2326.

Incyte Biosciences UK Ltd. Ponatinib 15 mg tablets. Summary of Product Characteristics. July 2022. Available at: https://www.medicines.org.uk/emc/product/1212/smpc [Last accessed 9/11/23]

Jabbour E, Kantarjian H, Cortes J. Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 2015;15(6):323-334.

Janssen L, Blijlevens NMA, Drissen MMCM, Bakker EA, Nuijten MAH, Janssen JJWM, et al. Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity. Haematologica 2021;106(7):1876-1882.

Medac. Hydroxycarbamide 500 mg capsules. Summary of Product Characteristics. February 2023. Available at: https://www.medicines.org.uk/emc/product/254/smpc [Last accessed 07/11/2023]

Mylan. Dasatinib 100 mg tablet. Summary of Product Characteristics. 25 July 2023. Available at: https://www.medicines.org.uk/emc/product/14399/smpc. [Last accessed: 9/11/23]

National Institute for Health and Care Excellence (NICE). Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors. Technology appraisal guidance [TA813]. Published: 03 August 2022. Available at:  https://www.nice.org.uk/guidance/ta813

National Institute for Health and Care Excellence (NICE). Bosutinib for previously treated chronic myeloid leukaemia. Technology appraisal guidance [TA401] Published: 24 August 2016. Available at: https://www.nice.org.uk/guidance/ta401

National Institute for Health and Care Excellence (NICE). Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia. Technology appraisal guidance [TA425]. Published: 21 December 2016. Available at: https://www.nice.org.uk/guidance/ta425

National Institute for Health and Care Excellence (NICE). Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. Technology appraisal guidance [TA426] Published: 21 December 2016. Available at: https://www.nice.org.uk/guidance/ta426

National Institute for Health and Care Excellence (NICE). Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia. Technology appraisal guidance [TA451] Published: 28 June 2017. Available at: https://www.nice.org.uk/guidance/ta451 [Last accessed 9/11/23]

Novartis Pharmaceuticals. Imatinib 100 mg tablets. Summary of Product Characteristics. October 2023. Available at: https://www.medicines.org.uk/emc/product/7779/smpc [Last accessed 9/11/23]

Novartis Pharmaceuticals. Nilotinib 150 mg capsules. Summary of Product Characteristics. October 2023. Available at: https://www.medicines.org.uk/emc/product/5852/smpc [Last accessed 9/11/23]]

Pfizer Limited. Bosutinib 100 mg tablet. Summary of Product Characteristics. 15 May 2023. Available at: https://www.medicines.org.uk/emc/product/3147/smpc. [Last accessed: 9/11/23]

Radivoyevitch T, Jankovic GM, Tiu RV, Saunthararajah Y, Jackson RC, Hlatky LR, et al. Sex differences in the incidence of chronic myeloid leukemia. Radiat Environ Biophys 2014;53(1):55-63.

Saglio G, Gale RP. Prospects for achieving treatment-free remission in chronic myeloid leukaemia. Br J Haematol 2020;190(3):318-327.

Smith G, Apperley J, Milojkovic D, Cross NCP, Foroni L, Byrne J, et al; British Society for Haematology. A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia. Br J Haematol 2020;191(2):171-193. Soverini S, Mancini M, Bavaro L, Cavo M, Martinelli G. Chronic myeloid leukaemia: the paradigm of targeting oncogenic tyrosine kinase signalling and counteracting resistance for successful cancer therapy. Mol Cancer 2018;17(1):49

Swerdlow SH, Campo E, Harris NL, Jaffa ES, Pileri SA, Stein H, Thiele J (Eds): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). IARC: Lyon 2017.

Westerweel PE, Te Boekhorst PAW, Levin MD, Cornelissen JJ. New approaches and treatment combinations for the management of chronic myeloid leukaemia. Front Oncol 2019;9: Art 665.